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Introduction 
The first oral direct-acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) infection, 
the protease inhibitors telaprevir and boceprevir, were approved in 2011 [1]. Their antiviral 
efficacy was limited and they had to be combined with pegylated interferon (IFN) and ribavirin 
(RBV) and were associated with a high risk of serious adverse effects [2, 3]. The next generation 
of more potent and better tolerated DAAs was approved by the European Medicines Agency in 
2014, and includes the polymerase inhibitor sofosbuvir, the NS5A replication complex inhibitor 
daclatasvir, and the protease inhibitor simeprevir [4]. Since then, additional DAAs from different 
drug classes have been approved [4]. INF-free DAA combination therapy is now considered the 
standard of care for treatment of chronic hepatitis C, and DAAs are included in the WHO list of 
essential medicines [5]. HCV cure rates greater than 95% have been reported with similar 
treatment outcomes in both HCV mono-infected and HIV/HCV co-infected individuals [6]. Due 
to the negative impact of immunosuppression on progression of liver fibrosis, HIV/HCV co-
infected individuals are considered a group with high priority of HCV therapy [7]. However, the 
high market price of branded DAAs limits the access to this treatment even among some high-
income countries [8]. Furthermore, there is a high variability in market prices for DAAs, 
particularly in high-income countries, with little correlation between drug prices and gross 
national income [9]. Although a marked increase since 2014 in uptake of DAAs among 
HIV/HCV individuals in Europe is anticipated, their use is expected to vary significantly across 
Europe, reflecting differences in affordability and prioritization within the healthcare systems as 
well as differences in the burden of liver fibrosis across Europe. In some countries and particular 
patient groups, IFN-based therapy might still be used. The aim of this study was to investigate 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
regional differences in the rate of HCV treatment uptake, and type of therapy used among 
HIV/HCV co-infected patients in the pan-European EuroSIDA study after 2011. 
METHODS 
Study population and data collection 
Patients were included from the EuroSIDA study, a large prospective observational cohort of 
more than 22000 HIV-1 positive patients followed in 100 hospitals in 35 European countries plus 
Israel and Argentina [10]. Patients were enrolled into ten cohorts from 1994 onward. In cohort 1-
9, consecutive HIV positive patients older than 16 years of age were enrolled irrespective of 
HCV status. In cohort ten all HIV positive patients were also required to be positive for anti-
HCV antibodies (HCV-RNA positive or negative). At recruitment, in addition to demographic 
and clinical data, a complete ART history is obtained together with the most recent CD4 cell 
counts and HIV-RNA measurements, as well as anti-HCV, HCV-RNA, HCV genotype, hepatitis 
B surface antigen (HBsAg) and HBV-DNA. Data is collected prospectively at clinical sites and 
sent to the coordinating centre at 6 monthly intervals. At each follow-up visit, all CD4 cell 
counts, HIV-RNA, anti-HCV, HCV-RNA, genotype, HBsAg and HBV-DNA results measured 
since last follow-up are collected, and the start and stop dates for antiretroviral drugs and HCV 
and HBV drugs.  Detailed information about data collected in EuroSIDA can be found at 
http://www.chip.dk/Ongoing-Studies/EuroSIDA/About. 
All HCV-RNA positive patients, with prospective follow up after January 1 2011 (when the first 
DAAs were introduced) were eligible for this study. Median last follow up date was June 2016.   
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Classification of liver fibrosis stage 
Liver fibrosis stage, according to the METAVIR classification [11], was defined using data from 
liver biopsies, fibroscan, the aspartate aminotransferase to platelet ratio index (APRI) or from 
plasma hyaluronic acid, as previously described [12].  F4 fibrosis was defined from validated 
liver biopsy, fibroscan measurements greater than 12.5 kPa, an APRI score >2 and hyaluronic 
acid measurements >250 ng/ml. Fibrosis values at any given time point were the last values 
measured before the time point in question and where more than one measurement of fibrosis 
was recorded on the same date, the biopsy was assumed to be the gold standard, followed by 
fibroscan, APRI then hyaluronic acid.   
HCV treatment categories 
HCV treatment regimens were divided into three categories. 1) IFN +/- RBV (no DAA), 2) 
DAA+IFN +/- RBV, 3) DAA +/- RBV (no IFN). 
Statistical analysis 
Baseline was defined as the latest of 1 January 2011, recruitment to EuroSIDA, or testing HCV-
RNA positive. Regions of Europe were classified as in previous studies [13]. Based on country 
of residence, people were grouped into five regions: West: Austria, Belgium, France, Germany, 
Luxembourg, Switzerland. South: Argentina, Greece, Israel, Italy, Portugal, Spain. North: 
Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Sweden, United Kingdom. East 
Central: Bosnia-Herzegovina, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, 
Slovenia. East: Belarus, Estonia, Georgia, Latvia, Lithuania, Russia, Slovakia, Ukraine. 
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Characteristics at last visit for those not starting HCV treatment during follow up were compared 
to the characteristics at starting HCV treatment for those who started treatment during 
prospective follow-up. In those HCV-RNA positive, we calculated the incidence rate (IR) per 
1000 person years of follow-up (PYFU) for 1) starting any HCV treatment during follow-up and 
2) starting IFN-free DAA therapy. This analysis included follow up from baseline until last visit 
or first starting HCV treatment; patients may have been exposed to HCV treatment prior to 
baseline. 
Poisson regression was used to determine the factors associated with starting IFN-free DAA 
during prospective follow-up.  CD4 count , HIV viral load, starting combination antiretroviral 
therapy (cART), starting IFN/RBV only treatment, AIDS diagnosis, diagnosis of AIDS within 
the last 12 months (recent AIDS), fibrosis stage, HCV-RNA level, and HBsAg status were 
included as time-updated variables.  Other factors were fixed at baseline (gender, age, ethnic 
group, HIV transmission route, prior HCV treatment and CD4 nadir).  All variables were 
included in multivariate models.  In the Poisson regression model, Argentina was combined with 
Southern Europe, and 2011 and 2012 were combined as they had very similar incidence rate 
ratios of starting HCV treatment.  HIV viral load was categorised as <500 and >500. CD4 count 
was analysed as two categories (<350 and >350).  Neither prior AIDS nor recent AIDS was 
associated with starting DAA and therefore only prior AIDS was included in the final 
multivariate model.   
All analyses were performed using SAS version 9.4 (Statistical Analysis Software, Cary, NC, 
US).  
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RESULTS 
Incidence of starting any HCV therapy 
A total of 4308 HCV-RNA+ HIV positive persons were included in the study. Among included 
persons, 1255 (29.1%) were from Southern Europe and Argentina, while 970 (22.5%), 663 
(15.4%), 633 (14.7%), and 787 (18.3%) were from West, North, Central East and East, 
respectively. During 11863 PYFU, a median of 2.0 years per person (IQR 1.0–4.7), 1113 
(25.8%) started any HCV therapy (incidence 93.8/1000 PYFU; 95%CI 88.3–99.3). The 
incidence of starting therapy remained stable between 2011 (55.4/1000 PYFU; 95% CI 44.1–
66.7) and 2014 (65.0/1000 PYFU; 95% CI 53.3–76.7), but increased sharply in 2015 
(166.7/1000 PYFU; 95%CI 151.2-182.3) and 2016 (150.5/1000 PYFU; 95% CI 132.9–168.1).  
Patient characteristics at time of starting HCV therapy 
Table 1 shows the patient characteristics at time of starting any HCV treatment compared with 
last clinic visit in those untreated during follow up. The median age of treated and untreated was 
47 and 45 years, respectively, and around a third of all patients were HCV treatment 
experienced. Compared with untreated, HCV treated patients were less likely to be female (23% 
vs. 30%), come from Central East (10% vs. 16%) and East (12% vs. 21%) and have a history of 
injection drug use (54% vs. 60%), but more likely to have genotype 1 (44% vs. 39%) and 
cirrhosis (22% vs. 11%). Treated persons were slightly more likely to have suppressed HIV-
RNA (93% vs. 89%) whereas the median (IQR) CD4 count was similar [570 cells/mm3 (401–
770) vs. 548 cells/mm3 (364–773)]. The proportion of untreated patients with ≥F3 was similar 
when comparing South (54%) with West (52%) and North (50%), but substantially lower than in 
Central East (86%) and East (79%). 
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Use of different HCV treatment regimens 
Figure 1 shows the use of IFN-based and INF-free regimens between 2011 and 2016, stratified 
by region. In 2015 and 2016, almost 90% of persons starting HCV therapy received an IFN-free 
regimen (n=638/722; 88.4%), ranging from 38/61 (62.3%) in East to 249/258 (96.5%) in 
South/Argentina. Use of IFN+RBV in all regions in 2015 and 2016 was restricted to a few 
countries.  In 2015/2016, 66/722 (9.1%) persons from 16 different countries in all EuroSIDA 
regions started IFN+RBV.  In South, all who started IFN+RBV in 2015/2016 were genotype 1, 
while in other regions those starting IFN+RBV were from all genotypes. In Central East IFN-
based treatment was used exclusively until 2015. In 2015 and 2016 IFN-free regimens were used 
in 60% and 80% of treatments in Central East, respectively. In East, uptake of HCV therapy was 
generally low in the entire study period and dominated by IFN+RBV, although IFN-free therapy 
was used in almost 90% of those starting HCV treatment in 2016. Among 638 persons starting 
INF-free treatment in 2015 and 2016, the most commonly used regimen was 
sofosbuvir/ledipasvir +/- RBV (n=328, 51.4%) followed by ombitasvir/paritaprevir/ritonavir +/- 
dasabuvir +/- RBV (n=128, 20.1%) and sofosbuvir/daclatasvir +/- RBV (n=108, 16.9%).   
Incidence of starting IFN-free DAA HCV treatment 
638 (14.8%) persons started an IFN-free DAA regimen during 13043 PYFU (median follow-up 
2.3 years; IQR 1.3–5.1 years) with an overall incidence of 56.0/1000 PYFU (95% CI 51.9–60.0). 
The incidence of starting IFN-free DAA increased from 7.8/1000 PYFU (5.9–9.8) in 2014 or 
earlier to 135.2/1000 PYFU (122.0–148.5) in 2015 and 128.9/1000 PYFU in 2016 (113.5–
144.3), and varied significantly across regions (figure 2). The increase was highest in North and 
West and intermediate in South. From 2015 to 2016, the incidence decreased by 46% in South, 
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whereas the incidence continued to increase in West and North. In both Central East and East 
there was a modest increase in incidence in use of DAAs in 2015 and 2016.  
Within each region the uptake of IFN-free DAA varied substantially (figure 3). For example in 
West, which included six countries each with at least 30 persons under follow up in 2016, the use 
of DAA therapy varied from 4% to 62%. In East, uptake of DAA was less than 5% in four out of 
six countries. A notable exception is Georgia where 31% have been treated with DAAs as part of 
a national hepatitis C elimination program paid for by Gilead Sciences [14]. Among the 16 
countries which according to the study by Marshall et al [8] had no restrictions for 
reimbursement of IFN-free DAA based on both fibrosis stage and recent drug/alcohol 
dependence or that prioritized those HIV/HCV co-infected, the uptake of IFN-free DAA among 
persons under follow up in 2016 was only 22.2% in all countries combined, and exceeded 40% 
in just four countries (France, Iceland, Netherlands and Slovenia). 
Factors associated with starting IFN-free DAA treatment 
Figure 4 shows the adjusted incidence rate ratios of starting IFN-free DAA treatment during 
follow up. Females were less likely to start IFN-free DAA treatment [incidence rate ratio, IRR: 
0.77 (95% confidence interval, CI 0.63–0.93)], as were individuals from Central East (IRR 0.41, 
95% CI 0.29–0.56) vs. South, or East (IRR 0.47, 95% CI 0.32–0.68) vs. South. Persons with a 
history of injecting drug use (IDU) were less likely than non-IDU to start DAA (IRR 0.84, 95% 
CI 0.68–1.02), but the result did not reach statistical significance (p=0.080). HCV genotype 3 
(IRR 0.58, 95% CI 0.46–0.74) vs. genotype 1, and those who had not started cART (IRR 0.65, 
95% CI 0.49–0.87) vs. on cART and those with detectable HIV-RNA (IRR 0.44, 95% CI 0.29 – 
0.67) were also less likely to start DAA treatment.  In contrast, older persons (IRR 1.18, 95% CI 
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1.07–1.30) per 10 years older, those with HCV-RNA >500.000 IU/ml (IRR 1.28, 95% CI 1.08–
1.51) vs. ≤500.000 IU/ml and those with cirrhosis (IRR 4.40, 95% CI 3.63–5.33) vs. F0/F1, were 
more likely to start DAA.  After adjustment, there was no difference in the incidence of starting 
DAA-based HCV treatment comparing 2016 with 2015 (IRR 1.05, 95% CI 0.89–1.23; p=0.55). 
The gender effect was consistent across regions (p-value=0.51 for interaction between region and 
gender for starting IFN-free DAA), but was most pronounced in those younger than 35 years of 
age (IRR 0.20, 95% CI 0.055–0.73, p=0.015), while for those aged 35–50 and >50, there was a 
much smaller difference (IRR 0.79, 95% CI 0.61-1.01, p=0.061 and 0.78, 95% CI 0.57–1.06, 
p=0.11 respectively,  p=0.0001 for interaction between age and gender).  Adding type of cART 
regimen to the model showed that receiving an integrase inhibitor based regimen (compared with 
not receiving cART) was associated with a higher incidence of starting IFN-free DAA (IRR 
1.85, 95% CI 1.16–2.94), whereas both protease inhibitor and non-nucleotide reverse 
transcriptase inhibitor regimens were not (p>0.6). 
We performed a number of sensitivity analyses, restricting included patients to either those with 
F3 or F4 fibrosis at baseline, or those with a history of IDU, or excluding men who have sex with 
men, or including only countries with no restrictions for reimbursement according to Marshall et 
al [8]. In adjusted analysis, factors associated with starting IFN-free DAA therapy were very 
consistent and similar to the findings in the general analysis, although not all differences were 
statistically significant due to the reduced power of this analysis (results not shown). The only 
exceptions were that not receiving cART was no longer associated with starting IFN-free DAA 
in an adjusted analysis including only IDU (IRR 1.05, 95% CI 0.69-1.59, p=0.835), and adjusted 
analysis including only countries with no reimbursement restrictions showed the incidence of 
starting IFN-free DAA was lower in 2016 compared with 2015 (IRR 0.77, 95% CI 0.63–0.94, 
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p=0.0089). The IRR for comparing females with males was similar in all sensitivity analyses 
with the point estimate ranging from 0.77-0.87.  
DISCUSSION 
Among 4308 HIV/HCV co-infected persons followed in 35 European countries as well as Israel 
and Argentina, 26% started anti-HCV therapy between 2011 and 2016. The overall incidence of 
starting therapy remained relatively stable until 2014, but increased markedly in 2015. By 2014 
IFN-free DAA therapy was the predominant anti-HCV regimen used in Western Europe. The 
uptake of IFN-free treatment did not start to pick up until 2015 in Central East and East, and 
remained significantly lower than in the other regions.  
Since effective cART against HIV infection became available 20 years ago, its uptake has been 
lower in Eastern Europe compared with Western Europe [15]. History is now repeating itself 
with regards to effective and well-tolerated anti-HCV therapy.  Although several DAAs have 
been granted market authorization in the countries in East, prescription of the drugs are restricted 
by their high prices and lower purchasing power in this part of Europe [16]. Both Gilead 
Sciences [17] and Bristol-Myers Squibb [18] have signed license agreements that allow generic 
manufacturing of sofosbuvir/ledipasvir and daclatasvir for sale in more than 100 low- and middle 
income countries. However, among the countries in the EuroSIDA East region none are included 
in the access plans. Hence, HCV infected persons in general from this region have very limited 
access to DAAs via their healthcare system. The more affluent patients will be able to get DAAs 
outside the national healthcare system by buying generic DAAs directly from other countries or 
from buying them on the internet. One notable exception is Georgia that since April 2015 has 
had a national hepatitis C elimination program where all HCV infected persons are offered DAA 
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therapy paid for by Gilead Sciences [14]. Despite unrestricted access to free DAA, only 30% of 
Georgian patients included in this study had started treatment. 
Our study also documented large intra-regional variations in uptake of DAAs. Even though 
restrictions on reimbursement for DAAs have been removed gradually in many European 
countries during the study period [8], treatment uptake remained modest, even within countries 
with no reimbursement restrictions, although the numbers should be interpreted cautiously due 
few individuals under follow up in some countries. The World Health Organization has set a goal 
of eliminating HCV infection as a public health care threat by 2030 and recommends that all 
HIV/HCV co-infected persons are given effective treatment for both infections as a priority [19]. 
Our data indicates that by 2016 only few European countries are on track to achieve this goal. 
The incidence in uptake of DAA-based therapy continued to increase from 2015 to 2016 in all 
regions except South where it decreased by 46%. The reason for this sharp drop is unclear, but 
could be due to a “warehousing effect” where the high incidence in 2014 and 2015 was driven by 
large groups of patients who had waited for the introduction of effective therapy leaving fewer 
eligible for therapy in the remaining cohort.  
In 2015/2016 9% of all treatment regimens were IFN+RBV. The uptake of IFN+RBV was 
restricted to 16 countries from all regions of EuroSIDA, and used for all genotypes. IFN+RBV 
were until recently the recommended regimen for treatment of acute HCV infection [7]. Only 
nine out of 66 patients starting IFN+RBV in 2015/2016 had their first positive HCV-RNA in the 
12 months before starting treatment. Thus treatment of acute infection only plays a minor role in 
the continued use of IFN+RBV. 
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Although persons with cirrhosis were more likely to be prioritized for DAA treatment compared 
with persons with lower stages of fibrosis, 11% of untreated persons had signs of cirrhosis, and 
hence are at increased short-term risk of liver-related complications if they do not get access to 
effective HCV treatment. Reasons for not starting therapy are not collected in EuroSIDA, but in 
addition to non-availability of anti-HCV drugs, comorbidities, ongoing illicit drug or alcohol 
abuse and other causes of unstable life circumstances perceived to be associated with non-
adherence to therapy are likely reasons for not starting therapy. 
Women were also less likely to receive DAA therapy than men, even after adjustment for other 
factors associated with starting therapy. Large trials have found no differences in effectiveness 
and safety of DAAs according to gender [20, 21]. An earlier EuroSIDA study on the uptake of 
HCV treatment in the IFN era, found no differences according to gender [22]. The gender 
difference was most pronounced among those younger than 35 years of age, and was consistent 
across regions and in all sensitivity analyses. There were no gender differences in use of cART 
or proportion with suppressed HIV-RNA, but women had slightly longer times between CD4 and 
HIV-RNA measurements which might suggest less frequent clinic visit. DAAs are generally 
contraindicated during pregnancy and breastfeeding [23], but given the short duration of DAA 
therapy and the age distribution of the cohort, the effect of pregnancy on DAA uptake seems 
minimal. Residual confounding cannot be excluded. 
An important, but not unexpected finding was that lack of engagement in HIV care (defined as 
not receiving cART or having unsuppressed HIV-RNA) was associated with lower incidence of 
starting DAA. Hence barriers in the HIV care continuum are linked to poorer outcomes in HCV 
care, and should be addressed in a concerted manner to improve outcomes for both infections. 
There was a trend towards a lower incidence of DAA uptake among persons with a history of 
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IDU, although it did not reach statistical significance. Studies have confirmed that DAAs are 
effective among IDUs and guidelines recommend that all HCV infected persons, including IDUs, 
should be considered for therapy [7, 24].  
Study limitations 
This study has some limitations that should be mentioned.  
Although EuroSIDA seeks to include a representative sample of participants from all European 
countries, participants are mainly recruited from university clinics in large European cities and 
not in exact proportion to the infected population in each country, and may therefore not be 
representative of the entire HIV/HCV co-infected population in Europe. Among all anti-HCV 
positive individuals followed up after 2011, 1273 (17.9%) have unknown HCV-RNA status (not 
tested or not reported). Both factors might have led us to overestimate the incidence of HCV 
treatment, particularly in East where 710/1670 (42.5%) of all anti-HCV positive persons had 
unknown HCV-RNA. In the majority of participants, staging of liver fibrosis was based on 
APRI. Compared with liver biopsy, APRI is known to misclassify the fibrosis stage in some 
individuals, particularly in those with intermediate stage of fibrosis [25]. Furthermore, we not 
able to analyze the role of missed visits and/or frequency of visits for HIV care. The major 
strengths of this study is that it prospectively follows a large population of co-infected persons in 
a heterogeneous real-life setting across all regions of Europe, and that we have longitudinal data 
collected in a standardised way to allow temporal changes to be described. 
 CONCLUSIONS 
Although the use of effective and well-tolerated DAAs against HCV have increased markedly 
among HIV/HCV co-infected patients in Europe in general since 2014, cost of the drugs and 
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other barriers to treatment prevent them from reaching some of the patients most at need of HCV 
treatment. Further follow up to monitor access to DAA therapy to achieve the WHO HCV 
elimination goal in 2030 among HIV/HCV co-infected in Europe is warranted. 
NOTES 
Acknowledgements  
The multi-centre study group, EuroSIDA (national coordinators in parenthesis). 
Argentina: (M Losso), M Kundro, Hospital JM Ramos Mejia, Buenos Aires. Austria: (B 
Schmied), Otto Wagner Hospital, Vienna; R Zangerle, Medical University Innsbruck, 
Innsbruck. Belarus: (I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM 
Mitsura, Gomel State Medical University, Gomel; D Paduto, Regional AIDS Centre, 
Svetlogorsk. Belgium: (N Clumeck), S De Wit, M Delforge, Saint-Pierre Hospital, Brussels; E 
Florence, Institute of Tropical Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis 
Gent, Gent. Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar Univerziteta Sarajevo, 
Sarajevo. Croatia: (J Begovac), University Hospital of Infectious Diseases, Zagreb. Czech 
Republic: (L Machala), D Jilich, Faculty Hospital Bulovka, Prague; D Sedlacek, Charles 
University Hospital, Plzen. Denmark: G Kronborg,T Benfield, Hvidovre Hospital, Copenhagen; 
J Gerstoft, T Katzenstein, Rigshospitalet, Copenhagen; IS Johansen, Odense University Hospital, 
Odense; L Ostergaard, Skejby Hospital, Aarhus, L Wiese, Sjællands Universitetshospital, 
Roskilde; L N Nielsen, Hillerod Hospital, Hillerod. Estonia: (K Zilmer), West-Tallinn Central 
Hospital, Tallinn; Jelena Smidt, Nakkusosakond Siseklinik, Kohtla-Järve. Finland: (M Ristola), 
I Aho, Helsinki University Central Hospital, Helsinki. France: (J-P Viard), Hôtel-Dieu, Paris; P-
M Girard, Hospital Saint-Antoine, Paris; C Pradier, E Fontas, Hôpital de l'Archet, Nice; C 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Duvivier, Hôpital Necker-Enfants Malades, Paris. Germany: (J Rockstroh), Universitäts Klinik 
Bonn; G Behrens, Medizinische Hochschule Hannover; O Degen, University Medical Center 
Hamburg-Eppendorf, Infectious Diseases Unit, Hamburg; HJ Stellbrink, IPM Study Center, 
Hamburg; C Stefan, JW Goethe University Hospital, Frankfurt; J Bogner, Medizinische 
Poliklinik, Munich; G. Fätkenheuer, Universität Köln, Cologne. Georgia: (N Chkhartishvili) 
Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi. Greece:  (P 
Gargalianos), G Xylomenos, K Armenis, Athens General Hospital "G Gennimatas"; H 
Sambatakou, Ippokration General Hospital, Athens. Hungary: (J Szlávik), Szent Lásló Hospital, 
Budapest. Iceland: (M Gottfredsson), Landspitali University Hospital, Reykjavik. Ireland: (F 
Mulcahy), St. James's Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov Hospital, 
Tel Aviv; E Shahar, G Hassoun, Rambam Medical Center, Haifa; H Elinav, M Haouzi, Hadassah 
University Hospital, Jerusalem; D Elbirt, ZM Sthoeger, AIDS Center (Neve Or), 
Jerusalem. Italy: (A D’Arminio Monforte), Istituto Di Clinica Malattie Infettive e Tropicale, 
Milan; R Esposito, I Mazeu, C Mussini, Università Modena, Modena; F Mazzotta, A Gabbuti, 
Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di Roma la Sapienza, 
Rome; M Zaccarelli, A Antinori, R Acinapura, M Plazzi, Istituto Nazionale Malattie Infettive 
Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N Gianotti, Ospedale San Raffaele, Milan; 
M Galli, A Ridolfo, Osp. L. Sacco, Milan. Latvia: (B Rozentale), Infectology Centre of Latvia, 
Riga. Lithuania: (V Uzdaviniene) Vilnius University Hospital Santaros Klinikos, Vilnius; R 
Matulionyte, Centro poliklinika, Vilnius, Vilnius University Hospital Santaros Klinikos, 
Vilnius. Luxembourg: (T Staub), R Hemmer, Centre Hospitalier, 
Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum bij de Universiteit van 
Amsterdam, Amsterdam. Norway: (DH Reikvam), A Maeland, J Bruun, Oslo University 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Hospital, Ullevaal. Poland: (B Knysz), J Gasiorowski, M Inglot, Medical University, Wroclaw; 
E Bakowska, Centrum Diagnostyki i Terapii AIDS, Warsaw; R Flisiak,  A Grzeszczuk, Medical 
University, Bialystok; M Parczewski, K Maciejewska, B Aksak-Was, Medical Univesity, 
Szczecin; M Beniowski, E Mularska, Osrodek Diagnostyki i Terapii AIDS, Chorzow; T 
Smiatacz, M Gensing, Medical University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, 
Wojewodzki Szpital Specjalistyczny, Lodz; I Mozer-Lisewska, Poznan University of Medical 
Sciences, Poznan. Portugal: (L Caldeira), Hospital Santa Maria, Lisbon; K Mansinho, Hospital 
de Egas Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. Romania: (R Radoi), C 
Oprea, Spitalul Clinic de Boli Infectioase si Tropicale: Dr. Victor Babes, Bucuresti. Russia: (A 
Panteleev), O Panteleev, St Petersburg AIDS Centre, St Peterburg; A Yakovlev, Medical 
Academy Botkin Hospital, St Petersburg; T Trofimora, Novgorod Centre for AIDS, Novgorod, I 
Khromova, Centre for HIV/AIDS & and Infectious Diseases, Kaliningrad; E Kuzovatova, 
Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology named 
after Academician I.N. Blokhina, Nizhny Novogrod; E Borodulina, Vdoushkina, Samara State 
Medical University, Samara. Serbia: (D Jevtovic), The Institute for Infectious and Tropical 
Diseases, Belgrade. Slovenia: (J Tomazic), University Clinical Centre Ljubljana, 
Ljubljana. Spain: (JM Gatell), JM Miró, Hospital Clinic – IDIBAPS. University of Barcelona, 
Barcelona; S Moreno, JM Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A Jou, R 
Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol, Badalona; P Domingo, M 
Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau, Barcelona; JM Laporte, Hospital 
Universitario de Alava, Vitoria-Gasteiz. Sweden:  (K Falconer), A Thalme, A Sonnerborg, 
Karolinska University Hospital, Stockholm; CJ Treutiger, Venhälsan-Sodersjukhuset, 
Stockholm; L Flamholc, Malmö University Hospital, Malmö. Switzerland: (A Scherrer), R 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Weber, University Hospital Zurich; M Cavassini, University Hospital Lausanne; A Calmy, 
University Hospital Geneva; H Furrer, University Hospital Bern; M Battegay, University 
Hospital Basel; P Schmid, Cantonal Hospital St. Gallen.  
Ukraine:  A Kuznetsova, Kharkov State Medical University, Kharkov; G Kyselyova, Crimean 
Republican AIDS centre, Simferopol; M Sluzhynska, Lviv Regional HIV/AIDS Prevention and 
Control CTR, Lviv. United Kingdom: (B Gazzard), St. Stephen's Clinic, Chelsea and 
Westminster Hospital, London; AM Johnson, E Simons, S Edwards, Mortimer Market Centre, 
London; A Phillips, MA Johnson, A Mocroft, Royal Free and University College Medical 
School, London (Royal Free Campus); C Orkin, Royal London Hospital, London; J Weber, G 
Scullard, Imperial College School of Medicine at St. Mary's, London; A Clarke, Royal Sussex 
County Hospital, Brighton; C Leen, Western General Hospital, Edinburgh.  
 
The following centers have previously contributed data to EuroSIDA: 
Infectious Diseases Hospital, Sofia, Bulgaria 
Hôpital de la Croix Rousse, Lyon, France 
Hôpital de la Pitié-Salpétière, Paris, France 
Unité INSERM, Bordeaux, France 
Hôpital Edouard Herriot, Lyon, France 
Bernhard Nocht Institut für Tropenmedizin, Hamburg, Germany 
1st I.K.A Hospital of Athens, Athens, Greece 
Ospedale Riuniti, Divisione Malattie Infettive, Bergamo, Italy 
Ospedale di Bolzano, Divisione Malattie Infettive, Bolzano, Italy 
Ospedale Cotugno, III Divisione Malattie Infettive, Napoli, Italy 
Dérer Hospital, Bratislava, Slovakia 
Hospital Carlos III, Departamento de Enfermedades Infecciosas, Madrid, Spain 
Kiev Centre for AIDS, Kiev, Ukraine 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Luhansk State Medical University, Luhansk, Ukraine 
Odessa Region AIDS Center, Odessa, Ukraine 
 
EuroSIDA Steering Committee 
Steering Committee: : J Gatell, B Gazzard, A Horban, I Karpov, M Losso, A d’Arminio 
Monforte, C Pedersen, M Ristola, A Phillips, P Reiss, J Lundgren, J Rockstroh, A Scherrer, I 
Aho, LD Rasmussen, V Svedhem, G Wandeler, C Pradier, N Chkhartishvili, R Matulionyte, C 
Oprea, JD Kowalska, J Begovac, J Miro, G Guaraldi, R Paredes 
Chair: J Rockstroh 
Study Co-leads: A Mocroft, O Kirk 
 
EuroSIDA staff 
Coordinating Centre Staff: O Kirk, L Peters, A Bojesen, D Raben, D Kristensen, K Laut, JF 
Larsen, D Podlekareva, B Nykjær 
Statistical Staff: A Mocroft, A Phillips, A Cozzi-Lepri, L Shepherd, S Amele, A Pelchen-
Matthews 
 
 
 
 
  
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Reference List 
 
 1.  Edwards DJ, Coppens DG, Prasad TL, Rook LA, Iyer JK. Access to hepatitis C 
medicines. Bull World Health Organ 2015; 93(11):799-805. 
 2.  Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir 
versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of 
hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, 
controlled phase 2 trial. Lancet Infect Dis 2013; 13(7):597-605. 
 3.  Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et 
al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 
1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 
159(2):86-96. 
 4.  http://www.ema.europa.eu/ema/.Accessed 15 September 2017 
 5. 
 http://www.who.int/medicines/publications/essentialmedicines/20th_EML201
7_FINAL_amendedAug2017.pdf?ua=1. 
 6.  Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. 
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A 
Systematic Review. Ann Intern Med 2017; 166(9):637-648. 
 7.  EACS Guidelines, version 8.2, 2017. http://www.eacsociety.org/files/guidelines_8.2-
english.pdf.  
 8.  Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, et al. 
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs 
for HCV infection in Europe. Lancet Gastroenterol Hepatol 2018; 3(2):125-133. 
 9.  Andrieux-Meyer I, Cohn J, de Araujo ES, Hamid SS. Disparity in market prices for 
hepatitis C virus direct-acting drugs. Lancet Glob Health 2015; 3(11):e676-
e677. 
 10.  http://www.chip.dk/Ongoing-Studies/EuroSIDA/About.  
 11.  Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. 
The METAVIR Cooperative Study Group. Hepatology 1996; 24(2):289-293. 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 12.  Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, et al. 
Liver-related death among HIV/hepatitis C virus-co-infected individuals: 
implications for the era of directly acting antivirals. AIDS 2015; 29(10):1205-
1215. 
 13.  Peters L, Mocroft A, Lundgren J, Grint D, Kirk O, Rockstroh J. HIV and hepatitis C 
co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. BMC 
Infect Dis 2014; 14 Suppl 6:S13. 
 14.  Nasrullah M, Sergeenko D, Gvinjilia L, Gamkrelidze A, Tsertsvadze T, Butsashvili M, 
et al. The Role of Screening and Treatment in National Progress Toward 
Hepatitis C Elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep 
2017; 66(29):773-776. 
 15.  Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-
90-90 target be achieved? A systematic analysis of national HIV treatment 
cascades. BMJ Glob Health 2016; 1(2):e000010. 
 16.  Maistat L, Kravchenko N, Reddy A. Hepatitis C in Eastern Europe and Central Asia: 
a survey of epidemiology, treatment access and civil society activity in eleven 
countries. Hepatology, Medicine and Policy 2017. 
 17.  http://www.gilead.com/~/media/files/pdfs/other/hcv-generic-agreement-fast-facts-
111716.pdf. Accessed 15 September 2017 
 18.  https://www.bms.com/about-us/responsibility/access-to-medicines-in-the-developing-
world/hcv-developing-world-strategy.html . Accessed 15 September 2017 
 19.  WHO, Global Hepatitis Report, 2017. 
http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-
eng.pdf?sequence=1.  
 20.  Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir 
and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 
2015; 373(8):705-713. 
 21.  Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. 
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N 
Engl J Med 2015; 373(8):714-725. 
 22.  Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, et al. 
Temporal changes and regional differences in treatment uptake of hepatitis C 
therapy in EuroSIDA. HIV Med 2013. 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 23.  Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has 
anything changed for pregnant/lactating women? World J Hepatol 2016; 
8(12):557-565. 
 24.  EASL Recommendations on Treatment of Hepatitis C 2018. 
http://www.easl.eu/medias/cpg/2018/EASL%20Recommendations%20on%20
Treatment%20of%20Hepatitis%20C%202018/English-report.pdf.  
 25.  Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et 
al. A simple noninvasive index can predict both significant fibrosis and 
cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38(2):518-526. 
 
 
  
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Figure le
Figure 1
ribavirin,
by EuroS
 
gends 
: The figure
 PEG-IFN +
IDA region
 shows the p
 DAA, IFN
 
 
roportion o
-free DAA) 
f different H
started durin
CV treatme
g prospecti
nt regimens
ve follow up
 (PEG-IFN +
 and stratifi
 
ed 
 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Figure 2
follow up
 
: The figure
 and stratifi
 shows the i
ed by EuroS
 
ncidence of 
IDA region
starting IFN
 
-free DAA therapy during prospect
 
ive 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Figure 3
The figur
according
The bubb
each cou
 
 
e shows the
 to region o
le size and t
ntry 
 uptake of IF
f Europe an
he annotatio
 
N-free DA
d number of
n above eac
A therapy in
 HIV/HCV 
h bubble re
 34 individu
co-infected 
present the n
al EuroSID
under follow
umber of in
A countries 
 up in 2016
dividuals in
. 
 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Figure 4
during fo
The mod
CD4, pri
Abbrevia
up; HBsA
 
: The figure
llow up. 
el is adjuste
or AIDS, HB
tions: IDU: 
g: hepatitis
 shows the a
d for the fac
sAg, and H
injection dr
 B surface a
 
djusted inci
tors shown p
CV treatme
ug use; cAR
ntigen 
dence rate r
lus HIV tra
nt at baselin
T: combinat
atios of start
nsmission g
e 
ion antiretro
ing IFN-fre
roup, CD4 c
viral therap
e DAA thera
ell count, n
 
y;  FU: foll
py 
adir 
ow 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Table 1. Characteristics at time of starting HCV treatment or at last follow up in untreated 
  Total Untreated Started treatment P 
         
All  4308 100.0 3195 74.2 1113 25.8  
Gender Male 3110 72.2 2250 70.4 860 77.3 <0.0001
 Female 1198 27.8 945 29.6 253 22.7  
Race White 3842 89.2 2882 90.2 960 86.3 0.0003 
 Other 466 10.8 313 9.8 153 13.7  
Region South/Argen
tina 
1255 29.1 909 28.5 346 31.1 <0.0001
 West 970 22.5 638 20.0 332 29.8  
 North 663 15.4 468 14.6 195 17.5  
 Central East 633 14.7 523 16.4 110 9.9  
 East 788 18.3 657 20.6 130 11.7  
HIV risk MSM 808 18.8 546 17.1 262 23.5 <0.0001
 IDU 2531 58.8 1930 60.4 601 54.0  
 Hetero 636 14.8 486 15.2 150 13.5  
 Other/unkno
wn 
333 7.7 233 7.3 100 9.0  
HCV-
RNA 
<500.000 1586 36.8 1234 38.6 352 31.6 <0.0001
(IU/ml) >500.000 2579 59.9 1830 57.3 749 67.3  
 Unknown 143 3.3 131 4.1 12 1.1  
Genotyp
e 
Unknown 1223 28.4 931 29.1 292 26.2 0.026 
 1 1721 39.9 1234 38.6 487 43.8  
 2 81 1.9 62 1.9 19 1.7  
 3 799 18.5 613 19.2 186 16.7  
 4 484 11.2 355 11.1 129 11.6  
Fibrosis 0/1 2837 65.9 2273 71.1 564 50.7 <0.0001
Stage 2 482 11.2 331 10.4 151 13.6  
 3 303 7.0 172 5.4 131 11.8  
 4 585 13.6 339 10.6 246 22.1  
 Unknown 101 2.3 80 2.5 21 1.9  
 Yes 1370 31.8 994 31.1 376 33.8 0.099 
HCV Tx IFN/RBV 1206 28.0 863 27.0 343 30.8 0.015 
at  IFN/RBV/D
AA 
100 2.3 74 2.3 26 2.3 0.97 
baseline DAA only 107 2.5 99 3.1 8 0.7 <0.0001
HBsAg Negative 3714 86.2 2759 86.4 955 85.8 0.17 
 Positive 184 4.3 144 4.5 40 3.6  
 Unknown 410 9.5 292 9.1 118 10.6  
Ever No 305 7.1 213 6.7 92 8.3 0.073 
cART Yes 4003 92.9 2982 92.3 1021 91.7  
HIV- No 444 10.4 366 11.5 78 7.1 <0.0001
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RNA  
<500 Yes 3820 89.6 2803 88.5 1017 92.9  
  Median IQR Median IQR Median IQR P 
 
Age Years 45 38 – 51 45 37 – 50 47 40 - 52 <0.0001
CD4 /mm3 552 374 – 
772 
548 364 – 
773 
570 401 - 770 0.0070 
Last visit Mm/yy 06/16 6/15 – 
10/16 
8/16 2/16 – 
10/16 
5/15 01/14 – 
01/16 
<0.0001
Abbreviations: MSM: men who have sex with men; IDU: injection drug use; IFN: interferon; 
RBV: ribavirin; DAA: direct-acting antiviral; HBsAg: hepatitis B surface antigen; cART: 
combination antiretroviral therapy; IQR: interquartile range 
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